Medical News

RSS

Osiris second quarter biosurgery product revenue increases 43% from previous quarter

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the second quarter ended June 30, 2012.

30 Jul 2012

Positive results from Vermillion OVA500 multi-center study for ovarian cancer

Vermillion, Inc., a leading molecular diagnostics company, today announced positive results from a new prospective, multi-center clinical study of its ovarian cancer diagnostic OVA1.

30 Jul 2012

FDA clears Proteus ingestible sensor

Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration has cleared its ingestible sensor for marketing as a medical device. The ingestible sensor (formally referred to as the Ingestion Event Marker or IEM) is part of the Proteus digital health feedback system, an integrated, end-to-end personal health management system that is designed to help improve patients' health habits and connections to caregivers.

30 Jul 2012

Advaxis reports continued positive patient survival pattern in ADXS-HPV Phase 2 cervical cancer trial

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, presented updated preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

30 Jul 2012

Assay Depot launches virtual research laboratory

Assay Depot Inc. today announced the launch of a virtual research laboratory. Developed in partnership with AstraZeneca, the virtual laboratory is a powerful vendor relationship management (VRM) system that gives researchers easy access to a distributed network of thousands of research service providers located inside and outside the company.

30 Jul 2012

Tenth patient treated in ACT's hESC derived RPE cell trial for SMD

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

30 Jul 2012

MEDNAX acquires Anesthesia Medical Alliance of East Tennessee

MEDNAX, Inc., today announced the acquisition of Anesthesia Medical Alliance of East Tennessee a physician group practice based in Knoxville, Tenn. that provides anesthesia services at 16 practice locations throughout the East Tennessee region.

30 Jul 2012

First Edition: June 30, 2012

Today's headlines include recent reports about both the policies and politics related to the health law's implementation.

30 Jul 2012

Dosimetry data from SalutarisMD episcleral brachytherapy device clinical study on wet AMD

At the American Association of Physicists in Medicine (AAPM) Annual Meeting yesterday, Russell J. Hamilton, PhD, Professor and Physics Section Head, University of Arizona Department of Radiation Oncology, reviewed dosimetry data for a minimally invasive episcleral brachytherapy device developed by Salutaris Medical Devices, Inc. (SalutarisMD) to treat Wet AMD (Age-related Macular Degeneration), the leading cause of vision loss and blindness.

30 Jul 2012

FDA accepts Exelixis’ cabozantinib NDA for filing

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).

30 Jul 2012

Study extends scientific understanding of how pheromones activate the vomeronasal organ

The vomeronasal organ (VNO) is one of evolution's most direct enforcers. From its niche within the nose in most land-based vertebrates, it detects pheromones and triggers corresponding basic-instinct behaviors, from compulsive mating to male-on-male death matches. A new study from the Stowers Institute for Medical Research, published online in Nature Neuroscience on July 29, 2012, extends the scientific understanding of how pheromones activate the VNO, and has implications for sensory transduction experiments in other fields.

30 Jul 2012

Elsevier introduces Applied and Translational Genomics journal

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the launch of Applied and Translational Genomics, an open access journal.

30 Jul 2012

MCW, Transgenomic partner to offer next-generation genetic testing services

Transgenomic, Inc. and the Medical College of Wisconsin today announced a collaboration agreement under which Transgenomic will offer next-generation genetic testing services performed at the MCW Clinical Sequencing Program. These services will initially include Transgenomic's NuclearMitome Test for mitochondrial disorders.

30 Jul 2012

Combined approach reduces SSIs by 33% in patients after colorectal procedures

A surgical patient safety program that combines three components-accurate outcome measurement, support of hospital leadership, and engaged frontline providers-reduces surgical site infections (SSIs) by 33 percent in patients who undergo colorectal procedures, according to a new study published in the August issue of the Journal of the American College of Surgeons.

30 Jul 2012

Toshiba’s Vantage Titan 1.5T and 3T MR systems can help visualize CSF bulk flow

Cerebral Spinal Fluid (CSF), the clear water-like fluid that surrounds the brain and the spinal cord, plays a key role in maintaining balanced brain dynamics. For the first time, CSF bulk flow can now be visualized non-invasively with Toshiba America Medical Systems, Inc.'s Vantage Titan 1.5T and 3T MR systems.

30 Jul 2012

Ansell introduces GAMMEX Non-Latex Accelerator-Free Sensitive surgical glove with SENSOPRENE

Ansell Ltd., a global leader in protection solutions, has today introduced a ground-breaking new SENSOPRENE formulation, with the launch of its GAMMEX Non-Latex Accelerator-Free Sensitive surgical glove.

30 Jul 2012

PSA testing and early detection may prevent 17,000 men each year from prostate cancer

A new analysis has found that doing away with PSA (prostate specific antigen) testing for prostate cancer would likely cause three times as many men to develop advanced disease that has spread to other parts of the body before being diagnosed. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study suggests that PSA testing and early detection may prevent approximately 17,000 men each year from having such advanced prostate cancer at diagnosis.

30 Jul 2012

EASL calls on the UN to take action to fight against viral hepatitis infection

Marking World Hepatitis Day, the European Association for the Study of the Liver (EASL) calls on the different organizations which make up the United Nations systems to take action to fight against Viral Hepatitis (Hepatitis B and C), a potentially fatal infection of the liver which affects 500 million people.

30 Jul 2012

West Suffolk NHS Foundation Trust opt for Ascribe Emergency Department solution, Ascribe Symphony

Ascribe has announced today the order of its Emergency Department (ED) solution, Ascribe Symphony, by West Suffolk NHS Foundation Trust (WSFT).

30 Jul 2012

Boys show more preference to solve arithmetic problems than girls

In a University of Missouri study, girls and boys started grade school with different approaches to solving arithmetic problems, with girls favoring a slow and accurate approach and boys a faster but more error prone approach.

30 Jul 2012